BIIB
Income statement / Annual
Last year (2024), Biogen Inc.'s total revenue was $9.68 B,
a decrease of 1.62% from the previous year.
In 2024, Biogen Inc.'s net income was $1.63 B.
See Biogen Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$9.68 B |
$9.84 B |
$10.17 B |
$10.98 B |
$13.44 B |
$14.38 B |
$13.45 B |
$12.27 B |
$11.45 B |
$10.76 B |
| Cost of Revenue |
$2.31 B
|
$2.53 B
|
$2.28 B
|
$2.11 B
|
$1.81 B
|
$1.96 B
|
$1.82 B
|
$1.63 B
|
$1.43 B
|
$1.24 B
|
| Gross Profit |
$7.37 B
|
$7.30 B
|
$7.90 B
|
$8.87 B
|
$11.64 B
|
$12.42 B
|
$11.64 B
|
$10.64 B
|
$10.02 B
|
$9.52 B
|
| Gross Profit Ratio |
0.76
|
0.74
|
0.78
|
0.81
|
0.87
|
0.86
|
0.86
|
0.87
|
0.87
|
0.88
|
| Research and Development Expenses |
$2.49 B
|
$2.70 B
|
$2.60 B
|
$3.40 B
|
$4.53 B
|
$2.77 B
|
$2.71 B
|
$2.37 B
|
$1.97 B
|
$2.01 B
|
| General & Administrative Expenses |
$2.32 B
|
$2.43 B
|
$2.35 B
|
$2.58 B
|
$2.40 B
|
$2.28 B
|
$2.02 B
|
$1.86 B
|
$1.84 B
|
$2.00 B
|
| Selling & Marketing Expenses |
$66.80 M
|
$71.40 M
|
$54.10 M
|
$98.70 M
|
$111.80 M
|
$79.20 M
|
$90.20 M
|
$75.20 M
|
$106.30 M
|
$108.60 M
|
| Selling, General & Administrative Expenses |
$2.39 B
|
$2.50 B
|
$2.41 B
|
$2.68 B
|
$2.52 B
|
$2.36 B
|
$2.11 B
|
$1.94 B
|
$1.95 B
|
$2.11 B
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$250.50 M
|
$929.20 M
|
$988.10 M
|
$940.70 M
|
$506.50 M
|
| Operating Expenses |
$4.88 B
|
$5.20 B
|
$5.01 B
|
$6.08 B
|
$7.05 B
|
$5.38 B
|
$5.75 B
|
$5.30 B
|
$4.86 B
|
$4.63 B
|
| Cost And Expenses |
$7.19 B
|
$7.74 B
|
$7.28 B
|
$8.19 B
|
$8.85 B
|
$7.34 B
|
$7.56 B
|
$6.93 B
|
$6.30 B
|
$5.87 B
|
| Interest Income |
$67.60 M
|
$276.50 M
|
$89.30 M
|
$11.00 M
|
$42.00 M
|
$120.00 M
|
$112.50 M
|
$78.50 M
|
$63.40 M
|
$22.10 M
|
| Interest Expense |
$250.30 M
|
$246.90 M
|
$246.60 M
|
$253.60 M
|
$222.50 M
|
$187.40 M
|
$200.60 M
|
$250.80 M
|
$260.00 M
|
$95.50 M
|
| Depreciation & Amortization |
$673.20 M
|
$494.80 M
|
$518.40 M
|
$487.70 M
|
$457.20 M
|
$464.70 M
|
$650.50 M
|
$721.60 M
|
$637.20 M
|
$600.40 M
|
| EBITDA |
$3.00 B |
$2.38 B |
$3.54 B |
$3.92 B |
$5.11 B |
$7.74 B |
$7.01 B |
$6.61 B |
$6.35 B |
$5.62 B |
| EBITDA Ratio |
0.31
|
0.24
|
0.35
|
0.36
|
0.38
|
0.54
|
0.52
|
0.54
|
0.55
|
0.52
|
| Operating Income Ratio |
0.26
|
0.21
|
0.28
|
0.25
|
0.34
|
0.49
|
0.44
|
0.44
|
0.45
|
0.45
|
| Total Other Income/Expenses Net |
-$584.30 M
|
-$800.50 M
|
$705.30 M
|
-$1.01 B
|
$459.80 M
|
$3.90 M
|
$11.00 M
|
-$217.00 M
|
-$218.70 M
|
-$136.20 M
|
| Income Before Tax |
$1.91 B
|
$1.30 B
|
$3.59 B
|
$1.78 B
|
$5.05 B
|
$7.05 B
|
$5.90 B
|
$5.13 B
|
$4.93 B
|
$4.75 B
|
| Income Before Tax Ratio |
0.2
|
0.13
|
0.35
|
0.16
|
0.38
|
0.49
|
0.44
|
0.42
|
0.43
|
0.44
|
| Income Tax Expense |
$273.80 M
|
$135.30 M
|
$632.80 M
|
$52.50 M
|
$992.30 M
|
$1.16 B
|
$1.43 B
|
$2.46 B
|
$1.24 B
|
$1.16 B
|
| Net Income |
$1.63 B
|
$1.16 B
|
$3.05 B
|
$1.56 B
|
$4.00 B
|
$5.89 B
|
$4.43 B
|
$2.54 B
|
$3.70 B
|
$3.55 B
|
| Net Income Ratio |
0.17
|
0.12
|
0.3
|
0.14
|
0.3
|
0.41
|
0.33
|
0.21
|
0.32
|
0.33
|
| EPS |
11.2 |
8.02 |
20.97 |
10.44 |
24.86 |
31.47 |
21.62 |
11.94 |
16.96 |
15.38 |
| EPS Diluted |
11.19 |
7.97 |
20.87 |
10.4 |
24.8 |
31.42 |
21.58 |
11.92 |
16.93 |
15.34 |
| Weighted Average Shares Out |
$145.70 M
|
$144.70 M
|
$145.30 M
|
$149.10 M
|
$160.90 M
|
$187.10 M
|
$204.90 M
|
$212.60 M
|
$218.40 M
|
$230.70 M
|
| Weighted Average Shares Out Diluted |
$145.90 M
|
$145.60 M
|
$146.00 M
|
$149.60 M
|
$161.30 M
|
$187.40 M
|
$205.30 M
|
$213.00 M
|
$218.80 M
|
$231.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
